AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8461269 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 0
Study 8461269 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2946604 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate (Diane, 2 mg)
Number of subjects: 158
Study 2946604 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate (Androcur, 100 mg)
Number of subjects: 158
Study 31169293 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted inactivated A(H7N9) vaccine
Number of subjects: 0
Study 31169293 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted inactivated A(H7N9) vaccine
Number of subjects: 0
Study 28796885 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl aminolaevulinate photodynamic therapy (MAL-PDT)
Number of subjects: 35
Study 28796885 — intervention group
Group type: COMPARATOR
Intervention: Imiquimod (IMIQ)
Number of subjects: 35
Study 26903255 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral prevention (CBP) program
Number of subjects: 310
Study 26903255 — intervention group
Group type: COMPARATOR
Intervention: Usual community care (UC)
Number of subjects: 310
Study 24103087 — intervention group
Group type: EXPERIMENTAL
Intervention: Take-home naloxone (THN) training
Number of subjects: 187
Study 24103087 — intervention group
Group type: COMPARATOR
Intervention: Basic information on opioid overdose management (control)
Number of subjects: 187
Study 23101741 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Start Denver Model (ESDM)
Number of subjects: 48
Study 23101741 — intervention group
Group type: COMPARATOR
Intervention: Community intervention
Number of subjects: 48
Study 19602720 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuezhikang (n = 772)
Number of subjects: 1530
Study 19602720 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 758)
Number of subjects: 1530
Study 17764597 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-inactivated lactic acid-fermented oat gruel with added viable, lyophilized Lactobacillus plantarum 299v
Number of subjects: 18
Study 17764597 — intervention group
Group type: COMPARATOR
Intervention: Heat-inactivated lactic acid-fermented oat gruel without added viable, lyophilized Lactobacillus plantarum 299v
Number of subjects: 18
Study 17764597 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 18
Study 15843914 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide (120 microg)
Number of subjects: 26
Study 15843914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 12197890 — intervention group
Group type: EXPERIMENTAL
Intervention: albendazole
Number of subjects: 23
Study 12197890 — intervention group
Group type: EXPERIMENTAL
Intervention: combined serological testing
Number of subjects: 23
Study 9807036 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid 500 mg twice daily
Number of subjects: 20
Study 9807036 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolrestat 200 mg/day
Number of subjects: 20
Study 9807036 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7880225 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 900
Study 7880225 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 900
Study 7880225 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine
Number of subjects: 900
Study 2509103 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase (SK arm)
Number of subjects: 393
Study 2509103 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase and Nitroglycerin (SK-NTG arm)
Number of subjects: 393
Study 2509103 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin alone (NTG arm)
Number of subjects: 393
Study 2509103 — intervention group
Group type: COMPARATOR
Intervention: Control (conventional therapy without acute catheterization)
Number of subjects: 393
Study 2509103 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase (SK arms)
Number of subjects: 393
Study 788451 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoxsuprine
Number of subjects: 0
Study 788451 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study 30353600 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated transition from oncological treatment to home-based specialized palliative care (SPC) and dyadic psychological support
Number of subjects: 258
Study 30353600 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 258
Study 27809351 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (20 mg/day) plus sertraline (200 mg/day)
Number of subjects: 66
Study 27809351 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus sertraline (200 mg/day)
Number of subjects: 66
Study 25268289 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic squats without vibration
Number of subjects: 21
Study 25268289 — intervention group
Group type: EXPERIMENTAL
Intervention: Static squats without vibration
Number of subjects: 21
Study 25268289 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic squats with 30‐Hz WBV
Number of subjects: 21
Study 25268289 — intervention group
Group type: EXPERIMENTAL
Intervention: Static squats with 30‐Hz WBV
Number of subjects: 21
Study 24045883 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (300 mg/d)
Number of subjects: 83
Study 24045883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 22267349 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentored doctors
Number of subjects: 64
Study 22267349 — intervention group
Group type: COMPARATOR
Intervention: Non-mentored doctors
Number of subjects: 64
Study 19863279 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine inhalation challenge
Number of subjects: 57
Study 19863279 — intervention group
Group type: COMPARATOR
Intervention: Methacholine inhalation challenge
Number of subjects: 57
Study 17302253 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir (0.5 mg once daily for 48 weeks)
Number of subjects: 40
Study 17302253 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine (100 mg once daily for 48 weeks)
Number of subjects: 40
Study 14966092 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m(2) plus carboplatin AUC6
Number of subjects: 502
Study 14966092 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 225 mg/m(2) plus carboplatin AUC6
Number of subjects: 502
Study 11306394 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilatation followed by a self-catheterization regimen
Number of subjects: 753
Study 11306394 — intervention group
Group type: COMPARATOR
Intervention: Control group (men who did not develop anastomotic strictures)
Number of subjects: 753
Study 11306394 — intervention group
Group type: EXPERIMENTAL
Intervention: Stricture group (men who developed anastomotic strictures)
Number of subjects: 753
Study 9135312 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl 0.5 ml (25 micrograms)
Number of subjects: 60
Study 9135312 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 0.5 ml (control group)
Number of subjects: 60
Study 9135312 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal bupivacaine 0.5% 2 ml
Number of subjects: 60
Study 14502840 — intervention group
Group type: EXPERIMENTAL
Intervention: Low folate status
Number of subjects: 0
Study 14502840 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidemiological studies
Number of subjects: 0
Study 14502840 — intervention group
Group type: EXPERIMENTAL
Intervention: Potential inhibition of precursor lesions
Number of subjects: 0
Study 2444308 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine 7.5 mg daily
Number of subjects: 32
Study 2444308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 31482319 — intervention group
Group type: EXPERIMENTAL
Intervention: Fab antivenom (FabAV)
Number of subjects: 72
Study 31482319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 29781289 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Anterior (DA) approach
Number of subjects: 78
Study 29781289 — intervention group
Group type: COMPARATOR
Intervention: Direct Lateral (DL) approach
Number of subjects: 78
Study 27607187 — intervention group
Group type: EXPERIMENTAL
Intervention: solifenacin 5 mg
Number of subjects: 90
Study 27607187 — intervention group
Group type: EXPERIMENTAL
Intervention: darifenacin 7.5 mg
Number of subjects: 90
Study 27607187 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 90
Study 26325083 — intervention group
Group type: EXPERIMENTAL
Intervention: Premenopausal women
Number of subjects: 100
Study 26325083 — intervention group
Group type: COMPARATOR
Intervention: Postmenopausal women
Number of subjects: 100
Study 23803012 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigators met with intervention patients to provide transplant information and assistance.
Number of subjects: 167
Study 23803012 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control group).
Number of subjects: 167
Study 20107867 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anaesthesia with 0.5 ml preservative-free 1% intracameral lidocaine (2 drops of proxymethacaine 0.5%)
Number of subjects: 54
Study 20107867 — intervention group
Group type: COMPARATOR
Intervention: Subtenon anaesthesia with 4 ml 2% lignocaine
Number of subjects: 54
Study 19441669 — intervention group
Group type: EXPERIMENTAL
Intervention: peg‐IFNalpha2a (n=18) or peg‐IFNalpha2b (n=8) plus RBV in standard doses
Number of subjects: 47
Study 19441669 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 47
Study 16025959 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Sanjiasan decoction (MSD), one dosage each day for three months.
Number of subjects: 68
Study 16025959 — intervention group
Group type: COMPARATOR
Intervention: Naofukang 0.8 g three times a day for three months (Control).
Number of subjects: 68
Study 14636753 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone 20mg per day
Number of subjects: 45
Study 14636753 — intervention group
Group type: COMPARATOR
Intervention: Nutrition alone
Number of subjects: 45
Study 10781760 — intervention group
Group type: COMPARATOR
Intervention: AAI pacing
Number of subjects: 21
Study 10781760 — intervention group
Group type: COMPARATOR
Intervention: DDD pacing from RV apex or high septum
Number of subjects: 21
Study 10781760 — intervention group
Group type: COMPARATOR
Intervention: VVI pacing from both RV sites
Number of subjects: 21
Study 10781760 — intervention group
Group type: COMPARATOR
Intervention: DDD pacing
Number of subjects: 21
Study 9060320 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. catheter (group A)
Number of subjects: 165
Study 9060320 — intervention group
Group type: COMPARATOR
Intervention: Vacutainer venipuncture (group B)
Number of subjects: 165
Study 9060320 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. catheter diameter
Number of subjects: 165
Study 1714951 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 100 mg/m2 day 1; Bleomycin 15 mg IV day 1, and 16 mg/m2/d CI days 1 to 5; Fluorouracil 650 mg/m2/d CI days 1 to 5 (PBF)
Number of subjects: 49
Study 6172999 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (1 mg . kg‐1, iv at 100 micrograms . kg‐1 . min‐1)
Number of subjects: 15
Study 6172999 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (50 micrograms . kg‐1 at 5 micrograms . kg‐1 . min‐1)
Number of subjects: 15
Study 31368756 — intervention group
Group type: EXPERIMENTAL
Intervention: Animated visualization intervention
Number of subjects: 96
Study 31368756 — intervention group
Group type: COMPARATOR
Intervention: Active control
Number of subjects: 96
Study 27759463 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab Q2W (80 mg every two weeks after a 160 mg starting dose)
Number of subjects: 3866
Study 27759463 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab Q4W (80 mg every four weeks after a 160 mg starting dose)
Number of subjects: 3866
Study 27759463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3866
Study 27759463 — intervention group
Group type: COMPARATOR
Intervention: Etanercept (50 mg bi-weekly)
Number of subjects: 3866
Study 27167403 — intervention group
Group type: EXPERIMENTAL
Intervention: Right prefrontal tDCS with visuospatial WM training
Number of subjects: 62
Study 27167403 — intervention group
Group type: EXPERIMENTAL
Intervention: Left prefrontal tDCS with visuospatial WM training
Number of subjects: 62
Study 27167403 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation with visuospatial WM training
Number of subjects: 62
Study 27167403 — intervention group
Group type: EXPERIMENTAL
Intervention: Right prefrontal tDCS with spaced training
Number of subjects: 62
Study 27167403 — intervention group
Group type: EXPERIMENTAL
Intervention: Right prefrontal tDCS
Number of subjects: 62
Study 25060189 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based participatory eye health intervention
Number of subjects: 97
Study 25060189 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 97
Study 22096031 — intervention group
Group type: EXPERIMENTAL
Intervention: High ST2 concentrations (>35 μg/L)
Number of subjects: 4426
Study 22096031 — intervention group
Group type: EXPERIMENTAL
Intervention: ST2 biomarker
Number of subjects: 4426
Study 22096031 — intervention group
Group type: COMPARATOR
Intervention: Ranolazine
Number of subjects: 4426
Study 18815445 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-current cardioversion (DCC)
Number of subjects: 374
Study 18815445 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological cardioversion
Number of subjects: 374
Study 18815445 — intervention group
Group type: COMPARATOR
Intervention: Wait-and-watch
Number of subjects: 374
Study 18815445 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-current cardioversion (DCC) vs Pharmacological treatment
Number of subjects: 374
Study 17206078 — intervention group
Group type: EXPERIMENTAL
Intervention: Bravo capsule
Number of subjects: 200
Study 17206078 — intervention group
Group type: COMPARATOR
Intervention: Conventional naso-oesophageal catheter
Number of subjects: 200
Study 15991867 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular botulinum toxin A (BTX‐A)
Number of subjects: 20
Study 15991867 — intervention group
Group type: COMPARATOR
Intervention: Structured rehabilitation (physiotherapy and occupational therapy three times a week for 6 months)
Number of subjects: 20
Study 16036283 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 1070
Study 16036283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1070
Study 16036283 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of nicotine dependence
Number of subjects: 1070
Study 16036283 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of baseline depression symptoms
Number of subjects: 1070
Study 10229308 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide
Number of subjects: 16
Study 10229308 — intervention group
Group type: COMPARATOR
Intervention: Diet
Number of subjects: 16
Study 8560678 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg daily bicalutamide
Number of subjects: 20
Study 8560678 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg daily bicalutamide
Number of subjects: 20
Study 8560678 — intervention group
Group type: COMPARATOR
Intervention: 450 mg bicalutamide
Number of subjects: 20
Study 1883258 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose right unilateral electroconvulsive therapy (378-mC charge)
Number of subjects: 38
Study 1883258 — intervention group
Group type: COMPARATOR
Intervention: Bilateral electroconvulsive therapy
Number of subjects: 38
Study 6948949 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic instruments
Number of subjects: 5
Study 6948949 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand instruments
Number of subjects: 5
Study 6948949 — intervention group
Group type: COMPARATOR
Intervention: Control (uninstrumented)
Number of subjects: 5
Study 30767156 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive Virtual Reality Environment (VRE) with Cognitive Behaviour Therapy (CBT); 1 session introducing CBT techniques and 4 VRE sessions
Number of subjects: 32
Study 30767156 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 32
Study 30767156 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive Virtual Reality Environment (VRE) with Cognitive Behaviour Therapy (CBT)
Number of subjects: 32
Study 30121698 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 11
Study 30121698 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 26771522 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 5 mg/Amlodipine 5 mg (Per/Amlo group)
Number of subjects: 0
Study 26771522 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 5 mg (Amlo group)
Number of subjects: 0
Study 26771522 — intervention group
Group type: COMPARATOR
Intervention: Perindopril 4 mg (Per group)
Number of subjects: 0
Study 25088349 — intervention group
Group type: EXPERIMENTAL
Intervention: VascuLuminator
Number of subjects: 226
Study 25088349 — intervention group
Group type: COMPARATOR
Intervention: Control group (no VascuLuminator)
Number of subjects: 226
Study 22785114 — intervention group
Group type: EXPERIMENTAL
Intervention: ramipril + high‐dose rapamycin (trough level 6‐8 ng/mL)
Number of subjects: 55
Study 22785114 — intervention group
Group type: EXPERIMENTAL
Intervention: ramipril + low‐dose rapamycin (trough levels 2‐4 ng/mL)
Number of subjects: 55
Study 22785114 — intervention group
Group type: COMPARATOR
Intervention: ramipril (Group A)
Number of subjects: 55
Study 20188315 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional therapy in combination with exercise training
Number of subjects: 199
Study 20188315 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 199
Study 17130281 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone and exercise
Number of subjects: 51
Study 17130281 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone alone
Number of subjects: 51
Study 17130281 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo and exercise
Number of subjects: 51
Study 17130281 — intervention group
Group type: COMPARATOR
Intervention: Placebo and no exercise
Number of subjects: 51
Study 17130281 — intervention group
Group type: COMPARATOR
Intervention: Exercise groups (oxandrolone and exercise, placebo and exercise)
Number of subjects: 51
Study 17130281 — intervention group
Group type: COMPARATOR
Intervention: Both exercise groups
Number of subjects: 51
Study 16355546 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental amalgam fillings
Number of subjects: 0
Study 11923049 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin plus conventional therapy
Number of subjects: 81
Study 11923049 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy alone
Number of subjects: 81
Study 10438381 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz, 600 mg daily
Number of subjects: 10
Study 7557702 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental referral form with a special area for the consultant to fill out and return to the referring family physician via the patient.
Number of subjects: 306
Study 7557702 — intervention group
Group type: COMPARATOR
Intervention: Routine referral form with the patient's name, age, and reason for consultation.
Number of subjects: 306
Study 31226959 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to high intensity exercise training (8 sessions × 1.5 hours, 12 hours total)
Number of subjects: 16
Study 31226959 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to high intensity exercise training
Number of subjects: 16
Study 29989171 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant (500 mg l-ascorbic acid and 450 IU dl-α-tocopherol acetate, 2 capsules/day for 8 weeks)
Number of subjects: 36
Study 29989171 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cellulose capsules of identical appearance)
Number of subjects: 36
Study 29989171 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant
Number of subjects: 36
Study 28036375 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonsillectomy
Number of subjects: 5831
Study 28036375 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 5831
Study 28036375 — intervention group
Group type: COMPARATOR
Intervention: Tonsillectomy and Control
Number of subjects: 5831
Study 25266929 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-week Internet-based guided self-help program based on exposure therapy with weekly student support
Number of subjects: 212
Study 25266929 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 212
Study 22755305 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Number of subjects: 60
Study 22755305 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 60
Study 19382890 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol valerate (E2V)
Number of subjects: 192
Study 19382890 — intervention group
Group type: EXPERIMENTAL
Intervention: 17beta‐estradiol
Number of subjects: 192
Study 19382890 — intervention group
Group type: COMPARATOR
Intervention: Epimedium pubescens decoction
Number of subjects: 192
Study 17699476 — intervention group
Group type: EXPERIMENTAL
Intervention: C.E.R.A. once monthly
Number of subjects: 572
Study 17699476 — intervention group
Group type: EXPERIMENTAL
Intervention: C.E.R.A. twice monthly
Number of subjects: 572
Study 17699476 — intervention group
Group type: COMPARATOR
Intervention: Epoetin
Number of subjects: 572
Study 15073671 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose ganciclovir (5 mg/kg intravenously [iv] twice daily)
Number of subjects: 48
Study 15073671 — intervention group
Group type: COMPARATOR
Intervention: Half-dose ganciclovir (5 mg/kg iv once daily) plus half-dose foscarnet (90 mg/kg iv once daily)
Number of subjects: 48
Study 12083045 — intervention group
Group type: EXPERIMENTAL
Intervention: Intestinal cleansers
Number of subjects: 90
Study 12083045 — intervention group
Group type: COMPARATOR
Intervention: No intestinal cleansers (Control)
Number of subjects: 90
Study 9669786 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (n = 586)
Number of subjects: 1168